U.S. License Holder:
Genentech
Date of License:
February-22-2013
Last Update:
Oct-23-2024
FDA-Approved Indications
KADCYLA (ado-trastuzumab emtansine) is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent for:
The treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: Received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy;
The adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.